Transactions

Royalty Pharma Acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU132) Across All Indications for $175 Million. Royalty Pharma Acquires $75 Million of Immunomedics Common Stock at $17.15 per share, a More Than 15% Premium over 15-Day Moving Average.

Dublin, Ireland and New York, NY (US) – February 27, 2017  — Perrigo Company plc (NYSE; TASE: PRGO) today announced it has signed a definitive agreement to divest its rights to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri® (natalizumab) to Royalty Pharma.

Royalty Pharma Buys 4.5 Percent Royalty on Worldwide Sales for $90 Million Plus $10 Million Equity in Cytokinetics. Cytokinetics Agrees to Exercise Option to Co-Fund Phase 3 Development Program Under Collaboration with Amgen for Increased Royalty and Co-Promotion Rights in North America New York,

Proceeds will fund research and scholarships; will also be shared with inventors. Los Angeles, CA (US) and New York, NY (US) – March 4, 2016  — UCLA and Royalty Pharma announced today that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi, whose

Largest pharmaceutical royalty purchase ever completed. Funds will be used to expand cystic fibrosis research, care and patient programs. New York, NY (US) – November 19, 2014  — Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned

Jim Reddoch, PhD, Royalty Pharma Executive Vice President for Research and Investments Joins Avillion Board. London (UK) and New York, NY (US) – May 6, 2014  — Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development

Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI). Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest – Acquisition Adds Global

New York, NY (US) – January 6, 2014  — Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash. The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec’s

Second drug with breakthrough therapy designation to receive FDA approval. Washington, DC (US) – November 13, 2013  — The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

Retains royalty rights to odanacatib and other Celera drug assets. Madison, NJ (US) and New York, NY (US) – July 18, 2013  — Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it has completed the sale of its rights to